CA2726426A1 - Diffuse large b-cell lymphoma markers and uses therefor - Google Patents

Diffuse large b-cell lymphoma markers and uses therefor Download PDF

Info

Publication number
CA2726426A1
CA2726426A1 CA2726426A CA2726426A CA2726426A1 CA 2726426 A1 CA2726426 A1 CA 2726426A1 CA 2726426 A CA2726426 A CA 2726426A CA 2726426 A CA2726426 A CA 2726426A CA 2726426 A1 CA2726426 A1 CA 2726426A1
Authority
CA
Canada
Prior art keywords
genes
hla
expression product
expression
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2726426A
Other languages
English (en)
French (fr)
Inventor
Lisa M. Rimsza
Michael L. Leblanc
Joseph M. Unger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Fred Hutchinson Cancer Center
Original Assignee
University of Arizona
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona, Fred Hutchinson Cancer Center filed Critical University of Arizona
Publication of CA2726426A1 publication Critical patent/CA2726426A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2726426A 2008-06-04 2009-06-04 Diffuse large b-cell lymphoma markers and uses therefor Abandoned CA2726426A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13102708P 2008-06-04 2008-06-04
US61/131,027 2008-06-04
PCT/US2009/046314 WO2009149297A1 (en) 2008-06-04 2009-06-04 Diffuse large b-cell lymphoma markers and uses therefor

Publications (1)

Publication Number Publication Date
CA2726426A1 true CA2726426A1 (en) 2009-12-10

Family

ID=41055125

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2726426A Abandoned CA2726426A1 (en) 2008-06-04 2009-06-04 Diffuse large b-cell lymphoma markers and uses therefor

Country Status (5)

Country Link
US (2) US20110159492A1 (https=)
EP (1) EP2297349A1 (https=)
JP (1) JP2011525106A (https=)
CA (1) CA2726426A1 (https=)
WO (1) WO2009149297A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101968491A (zh) * 2010-09-29 2011-02-09 上海生物芯片有限公司 弥漫性大b细胞淋巴瘤分子病理分型方法及试剂盒和应用
KR101320633B1 (ko) * 2011-05-25 2013-10-30 엠앤디 (주) 실시간 중합반응을 이용한 암의 진단을 위한 정보제공방법 및 이를 위한 암 진단용 키트
BR112013031019A2 (pt) * 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
US8592156B2 (en) 2011-08-08 2013-11-26 Roche Molecular Systems, Inc. Predicting response to anti-CD20 therapy in DLBCL patients
EP2568290B1 (en) 2011-09-12 2017-02-22 Atrys Health, SA Methods for prognosis of diffuse large B-cell lymphoma
EP2834007B1 (en) * 2012-04-04 2019-06-26 University of Cincinnati Device and method for sweat collection
MX2015006955A (es) 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
JP7357921B2 (ja) * 2017-09-29 2023-10-10 国立大学法人九州大学 びまん性大細胞型ｂ細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット
WO2019173991A1 (zh) * 2018-03-14 2019-09-19 深圳华大生命科学研究院 恶性淋巴瘤标志物及其应用
US20220002730A1 (en) * 2018-08-24 2022-01-06 City Of Hope Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer of activated b cells and the uses thereof
WO2021026335A1 (en) * 2019-08-08 2021-02-11 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
WO2022093910A1 (en) * 2020-10-27 2022-05-05 The Children’S Mercy Hospital Prognostic gene signature and method for diffuse large b-cell lymphoma prognosis and treatment
WO2025151077A1 (en) * 2024-01-08 2025-07-17 National University Of Singapore A method to predict and target resistance to chemotherapy in a cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5795716A (en) * 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5953727A (en) * 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
JP2001515234A (ja) * 1997-07-25 2001-09-18 アフィメトリックス インコーポレイテッド 多型性データベースを提供するためのシステム
US6232066B1 (en) * 1997-12-19 2001-05-15 Neogen, Inc. High throughput assay system
US6238869B1 (en) * 1997-12-19 2001-05-29 High Throughput Genomics, Inc. High throughput assay system
US6185561B1 (en) * 1998-09-17 2001-02-06 Affymetrix, Inc. Method and apparatus for providing and expression data mining database
CN100572535C (zh) * 2002-10-22 2009-12-23 卫材R&D管理有限公司 在分裂停止后的产多巴胺型神经元前体细胞中特异性表达的基因
US7332280B2 (en) * 2003-10-14 2008-02-19 Ronald Levy Classification of patients having diffuse large B-cell lymphoma based upon gene expression
US7939251B2 (en) * 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer

Also Published As

Publication number Publication date
US20150148254A1 (en) 2015-05-28
EP2297349A1 (en) 2011-03-23
US20110159492A1 (en) 2011-06-30
JP2011525106A (ja) 2011-09-15
WO2009149297A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
US20150148254A1 (en) Diffuse Large B-Cell Lymphoma Markers and Uses Therefor
Narrandes et al. Gene expression detection assay for cancer clinical use
JP6140202B2 (ja) 乳癌の予後を予測するための遺伝子発現プロフィール
JP5237076B2 (ja) 乳癌患者の診断および予後
JP6190434B2 (ja) 化学療法剤に対する応答を予測するための遺伝子発現マーカー
US7622260B2 (en) Diagnostic and prognostic tests
KR101443214B1 (ko) 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이
Abramovitz et al. A systems approach to clinical oncology: focus on breast cancer
EP3556867A1 (en) Methods to predict clinical outcome of cancer
WO2006091776A2 (en) Biomarkers for predicting prostate cancer progression
JP2008521412A (ja) 肺癌予後判定手段
WO2011086174A2 (en) Diagnostic gene expression platform
WO2013082440A2 (en) Methods of treating breast cancer with taxane therapy
Banneau et al. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations
EP2121988B1 (en) Prostate cancer survival and recurrence
EP3358020B1 (en) Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole blood
US20150344962A1 (en) Methods for evaluating breast cancer prognosis
KR101801980B1 (ko) 중추신경계 림프종 진단용 조성물 및 이를 이용한 중추신경계 림프종 진단 키트
US20180051342A1 (en) Prostate cancer survival and recurrence
KR101186721B1 (ko) 다환 방향족 탄화수소류에 대한 위해성 평가용 바이오마커 및 이의 용도
CN120989238A (zh) 用于鼻咽癌免疫治疗适用性的检测系统及方法
HK40014990A (en) Methods to predict clinical outcome of cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140604